SK Biopharma (KRX: 326030) Partners Insilico Medicine for AI Drug Discovery, Stock Rises

SK Biopharma (KRX: 326030) announced a partnership with Insilico Medicine on June 22, 2026, to utilize Insilico's artificial intelligence platform for discovering novel drug candidates targeting Central Nervous System (CNS) disorders. The news prompted a positive market reaction, with SK Biopharma's stock trading higher following the announcement. Under the agreement, Insilico Medicine will receive an undisclosed upfront payment and is eligible for milestone payments tied to various development and commercialization stages. The company will also receive royalties on the net sales of any successfully commercialized products resulting from the collaboration. This strategic alliance aims to accelerate the identification and development of new therapeutic options for CNS conditions, leveraging Insilico's AI-driven drug discovery capabilities to enhance SK Biopharma's pipeline.